Bladder Cancer Current Treatment Landscape

19 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Anne E. Lizardi, DNP, CRNP, RNFA, Johnson & Johnson Innovative Medicine, presents an overview of the bladder cancer treatment landscape. She explains how management is guided by disease stage and risk stratification and integrates intravesical therapy, systemic chemotherapy, and immunotherapy.

Dr. Lizardi outlines the American Urological Association (AUA) and National Comprehensive Cancer Network (NCCN) recommendations for non–muscle invasive bladder cancer, emphasizing the role of Bacillus Calmette-Guérin (BCG) in intermediate and high-risk disease. For BCG-unresponsive cases, she describes options including radical cystectomy and newly approved agents such as pembrolizumab, nadofaragene, and nogapendekin.
In muscle-invasive disease, the standard approach combines radical cystectomy with neoadjuvant cisplatin-based chemotherapy or bladder preservation using chemoradiation. Dr. Lizardi reviews adjuvant strategies involving nivolumab or pembrolizumab and highlights the evolving role of molecular and biomarker-driven therapies targeting FGFR2/3 and HER2.

The presentation reinforces guideline adherence, multidisciplinary care, and the use of next-generation sequencing to optimize treatment selection. The presentation concludes by emphasizing the integration of evidence-based guidelines, clinical judgment, and emerging technologies to improve patient outcomes in bladder cancer care.

And don't forget to join the GRU Community: https://grandroundsinurology.com/register/
Follow us on Twitter/X: https://x.com/GRUrology
And like and subscribe to us here on YouTube!

#BladderCancer #Urology #Oncology #Immunotherapy #BCGTherapy #CancerTreatment #GrandRoundsInUrology
Categoria
Oncology
Commenta per primo questo video.

Prossimo